Getting rid of MPO-ANCA: A matter of disease subtype

Rheumatology (United Kingdom)

Volumn 52, Issue 4, 2013, Pages 752-754

  Bremer, Jan P ^a   Csernok, Elena ^a   Holle, Julia ^a   Gross, Wolfgang L ^a   Moosig, Frank ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE;

ANCA ASSOCIATED VASCULITIS; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MEDICAL RECORD REVIEW; MICROSCOPIC POLYANGIITIS; PRIORITY JOURNAL; REMISSION;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BIOLOGICAL MARKERS; CHURG-STRAUSS SYNDROME; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; FOLLOW-UP STUDIES; HUMANS; MICROSCOPIC POLYANGIITIS; PEROXIDASE; RETROSPECTIVE STUDIES;

EID: 84875622623     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes412     Document Type: Letter

References (10)

1. Guillevin L, Durand-Gasselin B, Cevallos R et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999;42: 421-30.
2. Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003;115: 284-90.
3. Moosig F, Bremer JP, Hellmich B et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis 2012 published on 11 August 2012. doi:10.1136/annrheumdis-2012-201531.
4. Sinico RA, Di Toma L, Maggiore U et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005;52: 2926-35.
5. Sable-Fourtassou R, Cohen P, Mahr A et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005;143:632-8.
6. Masi AT, Hunder GG, Lie JT et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990;33:1094-100.
7. Watts R, Lane S, Hanslik T et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007; 66:222-7.
8. Mukhtyar C, Lee R, Brown D et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009;68:1827-32.
9. Suzuki K, Kobayashi S, Yamazaki K et al. Analysis of risk epitopes of anti-neutrophil antibody MPO-ANCA in vasculitis in Japanese population. Microbiol Immunol 2007; 51:1215-20.
10. Dörner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 2009;5:433-41.